HGH (Somatropin) in Canada: A Research Guide to Recombinant Human Growth Hormone

Why HGH deserves a dedicated Canadian research guide#

Human growth hormone searches in Canada attract a different reader from the typical peptide curiosity seeker. Many have already read about CJC-1295 with DAC, Ipamorelin, MK-677, or IGF-1 LR3, and still feel something is missing. What is missing is the molecule that sits at the top of the axis: growth hormone itself, not a secretagogue that stimulates its release, and not a downstream analogue that mimics its peripheral effector.

Northern Compound's growth-hormone archive covers every major secretagogue class: GHRH analogues such as CJC-1295 and Tesamorelin; GHRPs such as Ipamorelin and GHRP-6; and the oral ghrelin mimetic MK-677. We also cover the downstream mediator IGF-1 LR3. What was absent was a guide to the hormone those tools all converge on. Without HGH, the archive describes the accelerator, the signal splitter, and the pothole, but not the engine.

This article treats recombinant human growth hormone as research-use-only material. It does not provide dosing, route guidance for human use, anti-ageing protocols, body-composition advice, or medical recommendations. The goal is narrower and more useful: define the molecule, map its receptor biology, separate it from secretagogues and IGF-1 analogues, survey the evidence landscape, and explain what Canadian researchers should verify before putting a vial of rHGH into a protocol.

What HGH is at the molecular level#

Recombinant human growth hormone (rHGH, somatropin) is a single-chain polypeptide of 191 amino acids with a molecular weight of approximately 22.1 kDa. The sequence corresponds exactly to the major isoform of human pituitary GH. Two disulphide bridges stabilise the tertiary structure; there is no glycosylation. The molecule is produced through recombinant DNA technology in Escherichia coli or mammalian cells, then purified under conditions that preserve the native folding and disulphide bonding.

The recombinant origin matters for sourcing. rHGH is not a chemically synthesised peptide. It is a protein produced in a biological expression system, which means the analytical requirements differ from those for a 29-amino-acid GHRH analogue or a 7-amino-acid ACTH fragment. Host-cell proteins, endotoxin, residual DNA, aggregates, and misfolded isoforms are relevant impurities that do not exist for purely synthetic peptides. A supplier of research-grade rHGH should therefore provide analytical documentation appropriate for a recombinant protein, not a small-peptide COA template.

For receptor biology, the key fact is direct binding. HGH binds the growth hormone receptor (GHR), a class-1 cytokine receptor, at the cell surface. Two GH molecules bind to two GHR molecules in sequence, inducing receptor dimerisation, activation of the associated Janus kinase 2 (JAK2), and phosphorylation of intracellular tyrosine residues. These phosphorylated sites recruit signal transducer and activator of transcription 5 (STAT5), which dimerises, translocates to the nucleus, and drives transcription of target genes including IGF-1, SOCS2, and CIS.

This pathway is entirely distinct from the G-protein-coupled receptors used by GH secretagogues. CJC-1295 acts on the GHRH receptor (GHSR-1a is not involved); GHRP-6 and Ipamorelin act on the ghrelin receptor GHSR-1a; MK-677 is an oral GHSR-1a agonist. HGH skips all of those steps and acts directly on the GH receptor itself.

GH receptor signalling: JAK2/STAT5 and beyond#

The growth hormone receptor lacks intrinsic kinase activity. Instead, it associates constitutively with JAK2, a cytoplasmic tyrosine kinase. When HGH binds and induces receptor dimerisation, the two JAK2 molecules transphosphorylate each other, creating docking sites for downstream signalling proteins.

JAK2/STAT5 pathway#

The canonical GH pathway is JAK2/STAT5. Phosphorylated STAT5 proteins form homodimers or heterodimers, enter the nucleus, and bind to gamma-interferon-activated sequence (GAS) elements in the promoters of target genes. In the liver, this drives transcription of IGF-1, the primary mediator of many GH effects. In other tissues, STAT5 regulates genes involved in cell-cycle control, differentiation, and metabolic adaptation.

The transcriptional response is not instantaneous. STAT5 activation peaks within minutes of receptor engagement, but downstream gene expression changes build over hours. This temporal separation means that acute GH signalling and chronic GH exposure produce different transcriptional landscapes. A single GH pulse may trigger IGF-1 transcription robustly, while sustained GH exposure may upregulate negative feedback regulators such as SOCS2 and CIS, which inhibit further JAK2 signalling.

MAPK/ERK and PI3K/AKT pathways#

GH also activates the MAPK/ERK cascade through Shc recruitment and Ras activation, and the PI3K/AKT pathway through insulin receptor substrate (IRS) adaptor proteins. These pathways contribute to the proliferative, anti-apoptotic, and metabolic effects of GH, but they are not unique to GH signalling. Many growth factors converge on MAPK and PI3K, so researchers should use pathway-specific controls and avoid attributing every downstream change exclusively to GH.

IGF-1: the primary mediator#

The most important downstream output of GH signalling is IGF-1. In the liver, GH stimulates IGF-1 synthesis and secretion into the circulation, where it is bound to IGF-binding proteins and the acid-labile subunit. This endocrine IGF-1 mediates many of the anabolic and growth-promoting effects classically attributed to GH. However, local (paracrine/autocrine) IGF-1 produced in muscle, bone, cartilage, and other tissues may also contribute significantly to tissue-specific responses. The relative contributions of endocrine and local IGF-1 remain an active research question.

The GH-IGF-1 relationship is also why researchers must separate GH effects from IGF-1 effects. A compound that raises GH—such as Ipamorelin or CJC-1295—produces its tissue effects partly through GH receptor signalling and partly through the IGF-1 that GH induces. HGH produces both signals simultaneously because it is itself the GH signal, and it drives IGF-1 production as a downstream consequence. A direct IGF-1 analogue such as IGF-1 LR3 bypasses the GH receptor entirely and acts only on the IGF-1 receptor. These distinctions are not semantic; they determine which questions each tool can answer.

HGH versus GH secretagogues: direct versus indirect#

The difference between recombinant HGH and GH secretagogues is one of the most important conceptual boundaries in the growth-hormone literature, yet it is persistently blurred in supplier marketing and online discussion. A clear comparison prevents category errors.

The practical research implication is that HGH and secretagogues are not interchangeable. A protocol testing hypothalamic-pituitary regulation, GH pulsatility patterns, or feedback sensitivity should use a secretagogue. A protocol testing direct GH receptor signalling, tissue-level GHR responses, or comparisons between GH and IGF-1 signalling should use rHGH. Conflating the two classes produces confounded data.

HGH versus IGF-1 LR3: upstream versus downstream#

IGF-1 LR3 is the other common point of confusion. Because IGF-1 is the primary mediator of GH, some researchers assume that injecting IGF-1 LR3 is equivalent to injecting HGH, or that the two compounds are simply different points on the same line. They are not.

HGH acts on the GH receptor, which then drives IGF-1 production, but also activates JAK2/STAT5, MAPK/ERK, and PI3K/AKT pathways independently of IGF-1. Some GH effects—particularly on lipolysis, sodium retention, and insulin antagonism—are not mediated by IGF-1 at all. IGF-1 LR3 acts exclusively on the IGF-1 receptor, producing IGF-1 receptor-specific signalling through PI3K/AKT and MAPK/ERK, without any GH receptor engagement and without the endocrine pulsatility that GH provides.

For researchers studying the complete GH axis, both tools may be necessary. A protocol that uses HGH measures the full receptor-to-transcription cascade, including IGF-1 induction. A protocol that uses IGF-1 LR3 isolates the downstream IGF-1R signal. A protocol that combines both should include mechanistic justification and endpoints capable of distinguishing GH receptor effects from IGF-1 receptor effects.

Evidence map: what the preclinical literature actually shows#

The HGH literature is enormous, but much of it is clinical rather than preclinical, and much of the clinical work uses approved formulations for approved indications. A Canadian research guide must separate the regulatory streams and focus on evidence that is mechanistically informative without crossing into therapeutic recommendation.

Growth and development models#

The foundational HGH literature is in paediatric endocrinology. Recombinant HGH was developed to treat growth hormone deficiency in children, and the clinical validation of rHGH established that exogenous GH can restore linear growth when the endogenous axis is deficient. For research purposes, the key takeaway is not that rHGH "promotes growth" in a general sense, but that GH receptor signalling is necessary and sufficient for normal longitudinal bone growth in the presence of adequate nutrition and thyroid hormone.

Animal models of GH deficiency—such as the spontaneous dwarf rat, the GH-releasing hormone knockout mouse, and transgenic models with targeted GHR deletion—have confirmed that GH is required for postnatal growth, muscle development, and metabolic maturation. These models are useful for testing GH replacement strategies, GHR agonists, and pathway-specific interventions. They do not, however, establish that supraphysiological GH produces proportionally greater benefits in normal animals.

Body-composition models#

In adult models, GH has well-documented effects on lean mass, fat mass, and fluid balance. GH promotes lipolysis in adipose tissue, increases lean tissue mass in muscle, and expands extracellular fluid volume through sodium and water retention. These effects are dose-dependent and reversible upon cessation. The mechanism includes direct GH receptor signalling in adipocytes, IGF-1-mediated anabolic signalling in muscle, and renal sodium-handling changes.

The research value of these models is in understanding GH's role in metabolic regulation, not in designing body-composition interventions. The same effects that increase lean mass also alter glucose homeostasis, lipid profiles, and cardiovascular parameters. A protocol that measures only muscle or fat endpoints without assessing metabolic confounders is incomplete.

Bone and connective-tissue models#

GH is anabolic for bone through both direct GHR signalling in osteoblasts and IGF-1-mediated effects. In GH-deficient models, bone mineral density is reduced and fracture risk is increased. GH replacement restores bone turnover markers and improves density, though the response is slower than the muscle response. For researchers in orthopaedic or skeletal biology, GH is a relevant tool, but its effects must be distinguished from those of direct osteoanabolic agents such as parathyroid hormone or sclerostin inhibitors.

Metabolic and cardiovascular cautions#

GH is not a uniformly anabolic hormone. At supraphysiological concentrations, it induces insulin resistance through anti-insulin effects on muscle and adipose tissue, increases hepatic glucose output, and raises free fatty acid levels. These metabolic shifts are well documented and dose-dependent. A research protocol focusing on growth or body composition without measuring glucose, insulin, lipids, and inflammatory markers risks missing clinically relevant biology.

Cardiovascular effects include increased left ventricular mass, altered vascular tone, and changes in lipid profiles. Some of these effects are mediated by IGF-1; others are GH-specific. Researchers should not assume that because a model shows lean-mass gain, the overall physiological profile is benign.

Regulatory and research-use context in Canada#

Somatropin is a Schedule F drug in Canada, meaning it requires a prescription and is regulated as a biologic under the Food and Drugs Act. The approved indications include growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and small-for-gestational-age status with failure to catch up. These are specific clinical indications with established dosing, monitoring, and safety protocols.

Research-grade rHGH, when supplied for laboratory research rather than human therapeutic use, falls into a different regulatory category. It is not a drug, not a natural health product, and not a dietary supplement. Suppliers should label it research-use-only, avoid therapeutic claims, and provide documentation appropriate for a recombinant protein. Researchers should confirm that their institutional approvals, ethics protocols, and local regulations permit the use of recombinant GH in the intended experimental design.

The compliance boundary matters because HGH is frequently discussed in anti-ageing, athletic-performance, and body-composition contexts that border on therapeutic claims. Northern Compound does not endorse or describe such uses. This guide discusses the literature, the mechanism, and the sourcing standards. It does not describe protocols for people.

Sourcing standards: what a credible rHGH COA should include#

Because rHGH is a recombinant protein, the analytical expectations differ from those for chemically synthesised peptides. A supplier providing research-grade HGH should be able to demonstrate:

Identity#

• SDS-PAGE with Coomassie staining, showing a single band at approximately 22 kDa under reducing and non-reducing conditions.
• Western blot with an anti-HGH antibody, confirming immunoreactivity at the expected molecular weight.
• Mass spectrometry (ESI-MS or MALDI-TOF) confirming the expected molecular mass. For intact rHGH, high-resolution MS may be required to distinguish the target mass from aggregate or clipped forms.
• N-terminal sequencing or peptide mapping to confirm the first several amino acids match the expected sequence.

Purity#

• HPLC or UPLC purity under reversed-phase or size-exclusion conditions, with peak integration, method conditions, and lot number.
• Aggregate analysis by SEC-HPLC, because recombinant proteins are prone to non-covalent aggregation that can alter potency and immunogenicity.

Bioactivity#

• Cell-based bioassay, typically using the Nb2 rat lymphoma cell proliferation assay or a GH receptor reporter assay. The assay should include a reference standard for comparison.
• Specific activity expressed in international units (IU) per milligram, where available, to allow cross-lot consistency checks.

Safety#

• Endotoxin testing by LAL chromogenic or gel-clot assay, with a stated limit.
• Host-cell protein quantification where the expression system is bacterial.
• Residual DNA testing where applicable.
• Sterility testing if claimed.

Formulation#

• Net protein content per vial, not just total lyophilised mass.
• Excipient disclosure: mannitol, glycine, sodium phosphate, or other stabilisers should be listed.
• Storage guidance: typically lyophilised at -20 °C, protected from light, with stability data.

A supplier who provides only a headline purity percentage without method, lot, or identity data is not providing enough information for a recombinant protein. Researchers should demand the same rigour they would apply to any other biologic reagent.

Handling, storage, and preparation considerations#

Recombinant HGH is typically supplied as lyophilised powder with stabilising excipients. The general handling principles overlap with Northern Compound's reconstitution guide, but rHGH has additional considerations because of its size, structure, and propensity for aggregation.

Lyophilised vials should be stored at -20 °C or below, protected from light, and allowed to equilibrate to room temperature before opening to reduce condensation. Reconstitution should use sterile, pyrogen-free diluent appropriate for the study design. The diluent should be introduced slowly down the vial wall, and the solution should be swirled gently—not shaken—to avoid foaming and mechanical stress on the protein.

After reconstitution, the solution is more vulnerable to aggregation, oxidation, and adsorption to container surfaces. Aliquoting into single-use vials and avoiding repeated freeze-thaw cycles are essential. Visible turbidity, precipitates, or changes in colour indicate degradation and are grounds for discarding the material.

Because HGH is a protein, adsorption to glass and plastic can be significant at low concentrations. Pre-coating containers with a carrier protein or using low-binding plastics can reduce losses. The exact handling protocol should be documented in the laboratory notebook, including concentration, diluent, operator, date, and any deviations.

Common misrepresentations and red flags#

HGH marketing is some of the most misleading in the peptide space because the underlying biology is real enough to make claims sound plausible. Researchers should watch for five common distortions.

Conflation with secretagogues. A product page that describes GHRP-6, CJC-1295, and HGH as equivalent "GH peptides" is mechanistically wrong. The receptor targets, signalling pathways, pulsatility profiles, and regulatory categories are different. Researchers who treat them as interchangeable will obtain uninterpretable data.

Clinical-grade claims. No supplier of research-grade rHGH in Canada is providing a Health Canada-approved drug product unless they hold a drug establishment licence and the material is specifically released as such. Phrases such as "pharmaceutical grade," "clinical grade," or "GMP" should be supported by actual documentation of GMP certification and regulatory approval. Research-grade material is manufactured for laboratory use, not for human therapeutic administration.

Potency inflation. Some suppliers quote specific activities or purity percentages without method or reference standard. "99% pure" is meaningless without knowing whether the method was HPLC, SDS-PAGE, or densitometry, and without a chromatogram or gel image tied to the lot. For rHGH, bioactivity matters as much as purity: a pure but misfolded protein may have low or no activity.

Therapeutic drift. Product pages that mention anti-ageing, muscle building, fat loss, or performance enhancement are crossing from research description into therapeutic claim. A Canadian supplier making such claims for a Schedule F drug may be operating outside regulatory boundaries. Researchers should avoid suppliers whose language drifts in this direction.

Route confusion. Approved clinical rHGH is administered by subcutaneous injection. Research-grade rHGH is not formulated for other routes, and any protocol considering alternative delivery methods must address formulation, stability, sterility, and absorption questions that are outside the scope of standard product documentation.

Internal linking: where readers should go next#

The growth-hormone archive is designed as a connected map. A reader who understands this article should be able to move into adjacent guides without losing the mechanistic thread.

For the secretagogue perspective, start with the growth-hormone peptides guide. That article maps the full category: GHRH analogues, GHRPs, ghrelin mimetics, and the differences between them. It also explains the feedback loops that HGH bypasses.

For the downstream mediator, read the IGF-1 LR3 guide. That article explains the IGF-1 receptor, the PI3K/AKT pathway, and why direct IGF-1 analogues answer different questions from GH itself.

For GHRH analogues specifically, the CJC-1295 with DAC guide and the CJC-1295 without DAC guide explain the DAC distinction and its impact on pharmacokinetics and research design.

For the selective GHRP perspective, the Ipamorelin guide is the cleanest comparison: a compound that stimulates GH release with minimal spillover into cortisol or prolactin.

For supplier due diligence, the Canadian research peptide buyer guide covers COA evaluation, red flags, and the broader sourcing landscape.

For handling principles, the reconstitution guide provides foundational technique, though researchers should supplement it with supplier-specific guidance for recombinant proteins.

How HGH fits into an internal literature review#

A lab adding HGH to a growth-hormone literature review should resist the urge to treat it as the universal solution. The hormone is a tool for specific questions: direct GH receptor signalling, IGF-1 induction kinetics, pulsatile versus sustained GH exposure, metabolic effects of GH independent of IGF-1, and comparisons with secretagogue-driven GH release.

The review should begin with structure: record the sequence, molecular weight, expression system, and formulation. Then separate the evidence by model: GH deficiency, normal physiology, metabolic challenge, body composition, bone biology, cardiovascular parameters, and cell-culture signalling. Within each model, note the dose, route, timing, comparator, and endpoints. Only then should the review ask whether the findings converge.

A good review also records the negative space. What does HGH not do? It does not restore growth in the absence of adequate nutrition or thyroid hormone. It does not produce proportional benefits at supraphysiological concentrations. It does not replace IGF-1 receptor signalling. It does not eliminate the need for mechanistic controls. Naming those boundaries strengthens the research case rather than weakening it.

Study design: stronger alternatives to "growth" as an endpoint#

A strong rHGH study defines the biological question precisely. Vague endpoints such as "growth," "muscle gain," or "fat loss" belong in marketing, not in protocols.

For cell-culture work, useful endpoints include GH receptor dimerisation measured by bioluminescence resonance energy transfer, JAK2 phosphorylation by Western blot, STAT5 activation by electrophoretic mobility shift assay or phospho-specific antibody, IGF-1 transcript induction by quantitative PCR, and downstream target gene expression by RNA sequencing. Time-course matters: JAK2 peaks within minutes, STAT5 within 30–60 minutes, and transcriptional changes over hours.

For animal models, stronger endpoints include body weight and linear growth measured longitudinally, lean and fat mass by dual-energy X-ray absorptiometry or magnetic resonance imaging, IGF-1 serum concentrations by immunoassay, tissue IGF-1 transcript by qPCR, metabolic panels (glucose, insulin, lipids, free fatty acids), bone mineral density, and histological analysis of target tissues. A protocol that measures only body weight is missing the mechanistic layer.

For comparative studies, researchers should consider whether the experimental question requires HGH itself. If the goal is to test GH receptor signalling, rHGH is the direct tool. If the goal is to test the endogenous axis's response to stimulation, a secretagogue is more appropriate. If the goal is to test IGF-1 receptor signalling, IGF-1 LR3 is the direct tool. Choosing the wrong compound for the question is one of the most common design errors in the GH literature.

Why this guide does not include dosing#

Readers searching HGH Canada often expect practical guidance. Northern Compound intentionally does not provide it. Dosing, route, frequency, and personal-use protocols cross the line from literature review into medical or self-experimentation guidance. That is not the purpose of this site.

Even in preclinical research, doses cannot be copied across papers without validation. A microgram-per-kilogram regimen in a rat growth study does not translate directly to a cell-culture concentration. An approved clinical dose for paediatric GH deficiency does not translate to a research model of metabolic regulation. A body-composition protocol does not translate to a bone-density protocol.

The responsible approach is protocol-specific. A research team should derive exposure conditions from the exact literature model being tested, justify any deviations, run pilot validation where appropriate, document the lot and preparation workflow, and obtain ethics or institutional approval when required. Online anecdotes and supplier suggestions should not drive experimental design.

Practical checklist for Canadian HGH sourcing#

Before ordering or using a research-grade rHGH vial, a Canadian lab should be able to answer the following:

• Is the product explicitly labelled research-use-only?
• Does the supplier avoid therapeutic claims about growth, anti-ageing, muscle gain, fat loss, or performance enhancement?
• Does the COA match the exact lot being shipped?
• Does the documentation include SDS-PAGE, HPLC, or mass spectrometry tied to the lot?
• Is a bioactivity assay reported, with a reference standard or specific activity?
• Are endotoxin and host-cell protein limits stated?
• Is the net protein content per vial declared, not just total lyophilised mass?
• Are the excipients and formulation disclosed?
• Are storage conditions specific to the product rather than generic?
• Does the lab have a written protocol for reconstitution, aliquoting, storage, and disposal?
• Are endpoints defined in a way that matches the HGH literature being cited?
• Has the institution confirmed that the proposed use is compliant with local regulations?

If several of those answers are no, the problem is not administrative. It threatens the validity of the data and the compliance of the programme.

References and further reading#

• Baumann G.P. "Growth hormone doping in sports: a critical review of use and detection strategies." Endocrine Reviews (2012). PubMed.
• Brooks A.J. et al. "Mechanisms of activation and inhibition of the growth hormone receptor." Nature (2014). PubMed.
• Chhabra Y. et al. "Growth hormone receptor (GHR) arginine 274: a promising target for GHR antagonism." Endocrinology (2018). PubMed.
• Clark R.G. et al. "The growth hormone receptor: mechanism of receptor activation, cell signalling and aspects of the circulating hormone binding protein." Growth Hormone & IGF Research (1996). PubMed.
• Kopchick J.J. et al. "Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly." Endocrine Reviews (2002). PubMed.
• Lanning N.J. et al. "A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of the growth hormone receptor signalling." Cell Reports (2017). PubMed.
• List E.O. et al. "Review of the literature: liver-derived IGF-I and GH receptor signalling." Growth Hormone & IGF Research (2019). PubMed.
• Møller N. et al. "Metabolic effects of growth hormone in humans." Metabolism (1991). PubMed.
• Pollak M. "The insulin and insulin-like growth factor receptor family in neoplasia: an update." Nature Reviews Cancer (2012). PubMed.
• Savage M.O. et al. "Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society." Journal of Clinical Endocrinology & Metabolism (2009). PubMed.
• Sjögren K. et al. "Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice." Proceedings of the National Academy of Sciences (1999). PubMed.
• Vijayakumar A.D. et al. "Biology of the growth hormone receptor: molecular aspects and clinical relevance." Journal of Clinical Endocrinology & Metabolism (2021). PubMed.